HCW Biologics Files to Sell 3.4M Shares of Common Stock

Written by Emily J. Thompson, Senior Investment Analyst

HCWB-2.63%

Updated: Jan 09 2026

0mins

HCW Biologics files to sell 3.4M shares of common stock for holders

Discover Tomorrow's Bullish Stocks Today

Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.

Sign up now to unlock expert insights and stay one step ahead of the market trends.

HCWB

$1.11+Infinity%1D

Analyst Views on HCWB

Wall Street analysts forecast HCWB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCWB is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Analyst Rating

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.140

Low

8.00

Averages

8.00

High

8.00

Current: 1.140

Low

8.00

Averages

8.00

High

8.00

Maxim

Buy

downgrade

$120 -> $35

2025-05-29

Reason

Maxim

Price Target

$120 -> $35

AI Analysis

2025-05-29

downgrade

Buy

Reason

Maxim lowered the firm's price target on HCW Biologics to $35 from $120 but keeps a Buy rating on the shares. The firm cites the company's Q1 results and equity raise in adjusting its price target but also notes that HCW has made considerable progress in shoring up its balance sheet and advancing its pipeline following a challenging legal issue and arbitration, the analyst tells investors in a research note. The company should now have the capital to advance its pipeline and drive a turnaround in share value, Maxim added.

About HCWB

HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for HCWB?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy HCWB?

Get Started Free

Top News

HCW Biologics Files to Sell 3.4M Shares of Common Stock

Discover Tomorrow's Bullish Stocks Today

Analyst Views on HCWB

About HCWB

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Notice of Class Action Lawsuit Against Varonis Systems

Wall Street Ends Week Lower as Tech Stocks Sell Off

HCW Biologics Inc. (NASDAQ: HCWB) Engages in Virtual Investor "What This Means" Discussion

HCW Biologics Scientists to Showcase Three Posters at the 40th Annual Society for Immunotherapy of Cancer Meeting

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch